SCHEMBL4264845

SCHEMBL4264845

CN(N)C(=N)N(C)[C@H]1CC[C@H](N)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4264856 1.00
SCHEMBL4273422 0.73
SCHEMBL4273427 0.73
SCHEMBL4268624 0.73 FAAH (0.31)
SCHEMBL4264878 0.73 HSD11B1 (0.37)
SCHEMBL6156357 0.73 HSD11B1 (0.37)
SCHEMBL4269809 0.72
SCHEMBL4269805 0.72
SCHEMBL17729315 0.71 DPP4 (0.42)
SCHEMBL12980330 0.70 CA12 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485632-B2 Cephalosporins NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) 2009-02-03 US disclosed
EP-1529050-B1 CEPHALOSPORINS SANDOZ AG (CH) 2006-05-24 EP disclosed
US-20050234233-A1 e.g. 3-{(E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7- {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid; microbiocide; Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas NABRIVA THERAPEUTICS AG (AT) 2005-10-20 US disclosed
EP-1529050-A1 CEPHALOSPORINS Sandoz AG (CH) 2005-05-11 EP disclosed
WO-2004007505-A1 CEPHALOSPORINS SANDOZ AG (CH) 2004-01-22 WO disclosed